MMV533

Product vision
  • Uncomplicated malaria treatment and resistance management
MoA
  • Unknown. Inability to select resistant mutants
Key features
  • Rapid parasite killing in vitro and clearance in vivo
  • Long half-life in human
  • Predicted human dose of 40mg for a 12-log parasite killing
Status
  • First-in-human study ongoing
Next milestone
  • Complete phase I programme (including volunteer infection study)
Previously
  • SAR 441121. Full reference name is MMV688533
MMV Project Director
  • Dr BenoĆ®t Bestgen